已收盤 02-06 16:00:00 美东时间
+0.860
+3.71%
今日重点评级关注:RBC Capital:维持Compass Pathways"跑赢大市"评级,目标价从16美元升至21美元;RBC Capital:维持GH Research"跑赢大市"评级,目标价从33美元升至40美元
01-26 14:32
Morgan Stanley analyst Christopher Snyder initiates coverage on Mirion Technologies (NYSE:MIR) with a Equal-Weight rating and announces Price Target of $29.
01-23 20:16
U.S. stocks were higher, with the Dow Jones index gaining around 200 points on ...
01-10 00:25
Mirion Technologies Inc's (NYSE:MIR) short interest as a percent of float has r...
2025-12-15 23:01
今日重点评级关注:Ascendiant Capital:维持GRI Bio"买入"评级,目标价从35美元升至36美元;Ascendiant Capital:维持Atossa Therapeutics"买入"评级,目标价从7.75美元升至8美元
2025-12-09 10:32
Citigroup analyst Andrew Kaplowitz maintains Mirion Technologies (NYSE:MIR) with a Buy and lowers the price target from $35 to $33.
2025-12-09 03:25
今日重点评级关注:HC Wainwright & Co.:维持BiomX"买入"评级,目标价从15美元升至26美元;Clear Street:维持Diversified Energy"买入"评级,目标价从23美元升至25美元
2025-11-26 10:07
Evercore ISI Group analyst Nicholas Amicucci initiates coverage on Mirion Technologies (NYSE:MIR) with a Outperform rating and announces Price Target of $29.
2025-11-25 20:51
今日重点评级关注:康托·菲茨杰拉德:维持Cabaletta Bio"超配"评级,目标价从15美元升至30美元;HC Wainwright & Co.:维持Invivyd"买入"评级,目标价从5美元升至10美元
2025-11-03 20:20
今日重点评级关注:Ascendiant Capital:维持NRX Pharmaceuticals"买入"评级,目标价从46美元升至47美元;富国银行:维持Kyverna Therapeutics"超配"评级,目标价从27美元升至31美元
2025-10-31 10:25